Floatz logo

Indium-111-Dota-Labetuzumab-Irdye800Cw

Carcinoma

Radboud University Medical CenterradiopharmaceuticalPhase 1/2Dormant
CC
45/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
81/ 100

Competitive context

521 Active assets in the Carcinoma cohort.

Asset / SponsorPhaseRating
Adefovir
Bukwang Pharmaceutical
Phase 4BBB
Huaier Granule
Tongji Hospital
Phase 4BBB
Sorafenib
Bayer
Phase 4BBB
Carboplatin
AstraZeneca
Phase 4BB
Theprubicin
RWTH Aachen University
Phase 4BB

View all 50 →

Same molecule, other indications

Indium-111-Dota-Labetuzumab-Irdye800Cw is also rated in:

peritoneal carcinomatosisDormant
CC
Indicative ·
45 / 100
View asset →
digestive system cancerDormant
CC
Indicative ·
45 / 100
View asset →
neoplasmDormant
CC
Indicative ·
41 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →